Zura Bio (NASDAQ:ZURA – Get Free Report) and Aptose Biosciences (NASDAQ:APTO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
Insider & Institutional Ownership
61.1% of Zura Bio shares are held by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are held by institutional investors. 22.1% of Zura Bio shares are held by company insiders. Comparatively, 1.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Zura Bio has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zura Bio | N/A | N/A | -$69.24 million | N/A | N/A |
| Aptose Biosciences | N/A | N/A | -$51.21 million | ($2.97) | -0.07 |
Profitability
This table compares Zura Bio and Aptose Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zura Bio | N/A | -37.36% | -29.81% |
| Aptose Biosciences | N/A | -5,683.22% | -300.44% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Zura Bio and Aptose Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zura Bio | 0 | 1 | 5 | 1 | 3.00 |
| Aptose Biosciences | 0 | 0 | 3 | 0 | 3.00 |
Zura Bio currently has a consensus price target of $15.80, indicating a potential upside of 851.81%. Aptose Biosciences has a consensus price target of $4.33, indicating a potential upside of 2,030.45%. Given Aptose Biosciences’ higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Zura Bio.
Summary
Zura Bio beats Aptose Biosciences on 6 of the 9 factors compared between the two stocks.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
About Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
